Neumora Therapeutics, Inc. Common Stock (NMRA) Total Equity: History & Chart

Neumora Therapeutics, Inc. Common Stock(NMRA)

Biotechnology · Watertown, MA

$0.48-0.04 (-7.84%)

Delayed quote: Oct 6, 2026, 12:30 PM EDT

About Neumora Therapeutics, Inc. Common Stock

Neumora Therapeutics, Inc. is a specialized biopharmaceutical company progressing through clinical trials, dedicated to advancing therapies for a range of neurological, psychiatric, and neurodegenerative conditions. Its most advanced candidate, navacaprant (also known as NMRA-140), is a novel, once-daily oral kappa opioid receptor antagonist currently undergoing Phase 3 clinical trials for the management of major depressive disorder. Additionally, NMRA-511 is in Phase 1 studies, targeting agitation experienced by individuals with Alzheimer's-related dementia. Another compound, NMRA-266, is also in Phase 1 clinical development, aimed at addressing schizophrenia and other related neuropsychiatric conditions. Beyond its clinical programs, Neumora maintains a preclinical pipeline featuring several promising candidates: NMRA-NMDA for schizophrenia, NMRA-CK1d (a CK1d inhibitor initiative) for amyotrophic lateral sclerosis (ALS), NMRA-NLRP3 for specific neurodegenerative ailments, and NMRA-GCase for Parkinson's disease. Tracing its origins to a 2019 incorporation, the company, initially known as RBNC Therapeutics, Inc., adopted its current name, Neumora Therapeutics, Inc., in October 2021. Its corporate headquarters are situated in Watertown, Massachusetts.

Watertown, MA

63 employees

www.neumoratx.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Josh Pinto

View full financials

Total Equity

Basis: latest reported fiscal quarter. Source: stored company filings; unavailable inputs remain N/A.

The latest quarterly total equity is $44.52M with QoQ Growth of (37.01%). Total equity, also called shareholders' equity, is assets minus liabilities. The book value in P/B is the part attributable to common shareholders: total equity minus preferred stock.

Total Equity

NMRA Total Equity

$44.52M

Reported quarterly total equity; no daily interpolation. Q2 FY2026 (2026-06-30): $44.52M.

+147.17% over 10Y

NMRA P/B Ratio

Full P/B Ratio page

P/B Ratio

NMRA P/B Ratio Chart

2.01

FMP quote market capitalization / book value attributable to common shareholders (matching reported total stockholders equity minus preferred stock) Quote observation: 2026-10-06T16:33:47.863Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.

Quarterly Total Equity History

Period	Total Equity	QoQ Growth	YoY Growth
Q2 FY2026Period end 2026-06-30	$44.52M	(37.01%)	(75.66%)
Q1 FY2026Period end 2026-03-31	$70.68M	(31.95%)	(69.05%)
Q4 FY2025Period end 2025-12-31	$103.87M	(21.41%)	(63.82%)
Q3 FY2025Period end 2025-09-30	$132.16M	(27.73%)	(58.79%)
Q2 FY2025Period end 2025-06-30	$182.88M	(19.92%)	(52.03%)
Q1 FY2025Period end 2025-03-31	$228.36M	(20.45%)	(46.21%)
Q4 FY2024Period end 2024-12-31	$287.06M	(10.50%)	(38.80%)
Q3 FY2024Period end 2024-09-30	$320.74M	(15.87%)	(37.44%)
Q2 FY2024Period end 2024-06-30	$381.26M	(10.20%)	N/A
Q1 FY2024Period end 2024-03-31	$424.54M	(9.49%)	+16.07%
Q4 FY2023Period end 2023-12-31	$469.08M	(8.51%)	N/A
Q3 FY2023Period end 2023-09-30	$512.69M	N/A	N/A
Q2 FY2023Period end 2023-06-30	($513.54M)	N/A	N/A
Q1 FY2023Period end 2023-03-31	$365.77M	N/A	N/A
Q4 FY2022Period end 2022-12-31	($446.85M)	N/A	N/A
Q2 FY2022Period end 2022-06-30	($394.71M)	(7.84%)	N/A
Q1 FY2022Period end 2022-03-31	($366.02M)	(12.54%)	N/A
Q4 FY2021Period end 2021-12-31	($325.22M)	(8.25%)	N/A
Q3 FY2021Period end 2021-09-30	($300.45M)	N/A	N/A
Q4 FY2020Period end 2020-12-31	($94.38M)	N/A	N/A

Growth uses unique fiscal quarters. Missing or ambiguous prior periods render N/A.